Breaking news

Uzbekistan Fintech Uzum Valued At $2.3 Billion After New Funding

Uzbekistan’s fintech leader Uzum has achieved a remarkable $2.3 billion valuation, marking a 53% increase in just seven months. This surge comes on the back of a $131.5 million funding round led by sovereign wealth funds from Oman, with continued backing from investors such as Tencent, VR Capital, and FinSight Ventures.

The investment round comprises $81.5 million in equity and $50 million in convertible financing, positioning the startup for a potential pre-IPO raise of $250 million to $300 million in late 2026 or early 2027. Notably, this follows an earlier milestone when Uzum secured $65.5 million at a $1.5 billion valuation in August 2025, establishing it as the country’s first unicorn.

Building Uzbekistan’s Digital Ecosystem

Founded in 2022, Uzum operates a digital platform that combines e-commerce, payments and consumer lending services. The company initially launched Uzum Market as an online marketplace and later expanded its operations by introducing a digital bank, Uzum Bank, a consumer lending service called Uzum Nasiya and an express food delivery service known as Uzum Tezkor.

During its previous funding round, Uzum reported more than 17 million monthly active users. The platform now connects nearly 20 million users with more than 17,000 local sellers. Payment volume on the platform reached $11 billion in 2025. Annual transacting users increased from about 3 million to 4.6 million over the past year.

Fintech Driving Profitability

Fintech services represent a major source of revenue for the company. Uzum reported revenue growth from $505 million to $691 million in 2025, while net income increased from $150 million to $176 million. Its e-commerce division recorded $500 million in gross merchandise value and reached EBITDA profitability within three years of operation. The digital bank currently serves around 5 million customers and has issued 4.1 million debit cards. These cards represented nearly half of all debit cards issued in Uzbekistan in 2025. Uzum reports an unsecured loan portfolio of $400 million and a total financing volume of $1.2 billion. Management expects the bank to add about 5 million additional customers as lending and payment services expand.

The company is also expanding cross-border marketplace operations by integrating products from international suppliers. The platform now includes about 200 million SKUs from markets such as Turkey and China alongside roughly 1.5 million locally sourced products available for next-day delivery.

Investing In Infrastructure For Sustainable Growth

To support its expansive growth, Uzum has significantly invested in its logistics and physical infrastructure. The company currently operates approximately 1,500 pickup points across Uzbekistan, with plans to double that network by 2026. Additionally, its warehouse footprint is set to expand from 125,000 to roughly 500,000 square meters, facilitated by four new logistics centers.

Chief strategy and business development officer Nikolay Seleznev said direct investment in logistics remains necessary in markets where third-party fulfillment services are limited.

Positioning For A Global Stage

Uzum plans to use the new funding to expand fintech and commerce services, including additional ATMs, payment systems and point-of-sale infrastructure. The company is also considering several potential locations for a future public listing, including exchanges in the United States, Europe, the Middle East and Southeast Asia. Management has indicated that an initial public offering could take place within the next three years.

Novo Partners With Anthropic To Accelerate AI-Driven Drug Development

Danish pharmaceutical group Novo, formerly Novo Nordisk and best known for Ozempic, has partnered with Anthropic to accelerate drug development using artificial intelligence.

AI Expands Into Novo’s R&D

Under the agreement, Novo will use Anthropic’s models and Claude Science across its research and development operations. The company said the tools will support scientific reasoning, improve productivity and help researchers explore new approaches to understanding human biology and drug mechanisms.

“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,” Novo President and CEO Mike Doustdar said in a press release.

Anthropic CEO Dario Amodei said access to advanced AI models could help researchers shorten research timelines and improve drug discovery.

Novo Builds A Broader AI Strategy

The Anthropic partnership follows Novo’s separate agreement with OpenAI in April to use AI for analyzing complex datasets, identifying potential drugs and reducing the time between research and patient access.

Novo is also involved in Denmark’s AI infrastructure. In 2024, the Novo Nordisk Foundation partnered with Nvidia and the Export and Investment Fund of Denmark to establish the Danish Centre for AI Innovation, which operates the Gefion supercomputer.

Anthropic Expands In Life Sciences

Anthropic has also been expanding its presence in healthcare and pharmaceuticals. In May 2026, it announced a collaboration with Bristol Myers Squibb covering research, clinical development, manufacturing, commercial and corporate functions.

The Novo partnership adds another major pharmaceutical company to Anthropic’s life sciences business as drugmakers increasingly apply AI to research and development.

eCredo
The Future Forbes Realty Global Properties
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter